NumFin

Vertex Pharmaceuticals Incorporated

符号: VRTX

NASDAQ

400.16

USD

今天的市场价格

  • 28.4897

    市盈率

  • 1.0778

    PEG比率

  • 103.36B

    MRK市值

  • 0.00%

    DIV收益率

Vertex Pharmaceuticals Incorporated (VRTX) 财务报表

Download
年度季度
线性对数
在图表中，您可以看到 的动态默认数字 Vertex Pharmaceuticals Incorporated (VRTX). 的默认数据。公司收入显示 1515.622 M 的平均值，即 0.661 % 增长率。整个期间的平均毛利润为 1332.322 M，即 0.555 %. 平均毛利率为 0.989 %. 公司去年的净收入增长率为 0.090 %，等于 -0.366 % % 整个公司历史的平均增长率.,

年度季度
10Y20Y30Y40Y

资产负债表

深入分析 Vertex Pharmaceuticals Incorporated 的财务轨迹，我们可以看到其平均资产增长率。有趣的是，这一增长率为 ，反映了公司的高点和低点。与季度相比，这一数字调整为0. 回顾过去一年，总资产变化为 0.252. 在流动资产领域，VRTX 的报告货币为14144.2. 这些资产中的很大一部分，即 11221.5 是现金和短期投资。与去年的数据相比，该部分的变化率为0.041%. 公司的长期投资虽然不是其重点，但以报告货币计算的2596.4（如果有的话）为2596.4。这表明与上一报告期相比，2512.072% 的差异反映了公司的战略转变. 公司的债务概况显示，以报告货币计算的长期债务总额为 724.7. 这一数字表明，0.441% 的年同比变化. 股东权益总额所体现的股东价值是以报告货币计算的 17580.4. 这方面的年同比变化率为 0.264%. 深入了解公司财务信息后，会发现更多细节。应收账款净额的估值为1563.4，存货估值为 738.8，商誉估值为 1088（如有. 无形资产总额（如果有）按 839.9 估值.

common:word.in-mln

USD
Growth
TTM2023202220212020201920182017201620152014201320122011201020092008200720062005200420032002200120001999199819971996199519941993199219911990

balance-sheet.row.cash-and-short-term-investments

44800.111221.510778.57524.9
6658.9
3808.3
3168.2
2088.7
1434.6
1042.5
1387.1
1465.1
1321.2
968.9
1031.4
1284.9
832.1
460.9
704.6
361.2
392.3
583.2
635
743.2
388.6
31.5
24.2
71.5
34.9
28.4
71.6
28.6
11.6
27.6
4.4

balance-sheet.row.short-term-investments

25137.9849.2274.5729.9
670.7
699
518.1
423.3
250.6
327.7
761.8
895.8
831.8
493.6
788.2
838.3
443
105.2
491.5
283.1
337.3
485
526.9
554
66.5
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.net-receivables

6206.11563.41442.21136.8
885.4
633.5
409.7
281.3
201.1
177.6
73
85.5
143.3
183.1
12.5
9.6
23.5
31.3
62.9
20.6
11.9
7.3
13.2
20.3
12.3
5.9
0
0
0
0
0
0
0
0
0

balance-sheet.row.inventory

2566.1738.8460.6353.1
280.8
167.5
124.4
111.8
77.6
56.1
30.8
14.1
30.5
112.4
0
0
0
0
0
0
0
0
4.3
6.6
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.other-current-assets

2106.3620.574.4187.2
308.4
213.5
74
64
16.8
12.1
57.2
23.8
24.7
983.8
13.1
12.5
12
4.7
3.9
3.3
2.5
3.3
4
6
2.3
157.8
224.5
210.1
97.3
59.5
35.3
24.5
32.4
24.1
0.2

balance-sheet.row.total-current-assets

55678.614144.212681.39014.8
7825
4609.3
3702.3
2483.3
1761
1355.1
1548.1
1588.6
1589.6
1331.3
1057
1307
867.6
496.9
771.4
385.1
406.7
593.8
656.6
776.1
403.2
195.2
248.7
281.6
132.2
87.9
106.9
53.1
44
51.7
4.6

balance-sheet.row.property-plant-equipment-net

5782.11452.91108.41094.1
958.5
745.1
812
789.4
698.4
697.7
715.8
696.9
433.6
133.2
72.3
62.3
68.3
66.5
61.5
54.5
64.2
80.1
96
80.4
28.1
24.5
14.5
11.1
8.7
7.8
8.5
7.7
6.9
5
4.4

balance-sheet.row.goodwill

4352108810881402.2
1402.2
1402.2
50.4
50.4
50.4
50.4
39.9
31
31
31
26.1
26.1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.intangible-assets

2650.7839.9603.6400
400
400
0
29
284.3
284.3
29
105.8
663.5
663.5
518.7
518.7
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.goodwill-and-intangible-assets

7002.71927.91691.61402.2
1402.2
1402.2
50.4
79.4
334.7
334.7
68.9
31
694.5
694.5
544.8
544.8
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.long-term-investments

6735.22596.499.485.8
20.8
44.2
0
20.4
20.3
0
0
7.5
0
0
0
0
0
0
0
18.9
18.9
18.9
26.4
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.tax-assets

6439.11812.11246.9934.5
882.8
1190.8
1499.7
-20.4
-20.3
0
0
-7.5
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.other-non-current-assets

2142.1796.71323.3901.1
662.5
326.9
181.5
193.9
99.7
109.5
3.4
2.6
41.6
45.4
51.3
41.4
44.6
38.1
88.6
90.5
55.7
31.7
36.7
68.7
341.5
12.7
3.1
2.9
2.6
3.3
0.8
0.2
0.1
0.4
0.2

balance-sheet.row.total-non-current-assets

28101.285865469.64417.7
3926.8
3709.2
2543.6
1062.7
1132.8
1142
788.2
730.5
1169.7
873
668.4
648.5
112.9
104.6
150.2
163.9
138.7
130.6
159.1
149
369.7
37.2
17.6
14
11.3
11.1
9.3
7.9
7
5.4
4.6

balance-sheet.row.other-assets

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-assets

83779.822730.218150.913432.5
11751.8
8318.5
6245.9
3546
2893.8
2497
2336.3
2319
2759.3
2204.3
1725.4
1955.5
980.5
601.5
921.6
549
545.5
724.4
815.7
925.1
772.9
232.4
266.3
295.6
143.5
99
116.2
61
51
57.1
9.2

balance-sheet.row.account-payables

1427364.9303.9195
155.1
87.6
111
74
61.5
74.9
71.2
49.3
101.3
74.6
35.9
37
51.8
32.8
15.4
6.2
6.7
12.3
16.7
11.6
3.8
3
2.8
4.2
1.4
3
1.4
3.5
0.7
0.8
0

balance-sheet.row.short-term-debt

83.783.789.446.9
42.4
30.3
9.8
22.5
319.4
87
32
16.9
13.7
195.4
137
32.1
105.9
20
103.8
59.6
94.7
4.7
2.2
4.6
2.4
2.4
2.8
2.5
2.9
2.1
1.7
1.8
1.8
1.2
0.8

balance-sheet.row.tax-payables

99.599.5123.3211.3
104.2
72.3
0
0
6.9
31
10
8.4
0.7
12.1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.long-term-debt-total

3026.2724.7471.6556.7
581.5
577.4
567.2
563.9
838.2
820.6
825.3
440.9
672.6
400
400
153.8
287.5
0
20
180.1
335
340.7
325.9
323
347.3
4.7
7
5.9
5.6
4.9
4.7
4.2
3.3
2.1
2.4

Deferred Revenue Non Current

-924.1-924.100
0
88.8
82.6
80.2
12.6
26
45.3
71
123.8
118.1
160
38.2
247.5
101.2
116.3
0.9
18.3
51.8
46.6
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.deferred-tax-liabilities-non-current

924.1---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

balance-sheet.row.other-current-liab

11844.12928.51877.71460
1171
1024.3
40.6
473.2
-452.3
328.1
247.6
310.1
290.1
405.6
227.3
296.9
21.3
121
98
3
4.7
114.4
33.8
35.8
32.4
13.1
7.5
7
2.8
3.7
2.9
2
1.4
0.7
0.8

balance-sheet.row.total-non-current-liabilities

62591602.41807.61458.9
1504.9
1028.7
1095.2
1503.7
1547.6
1404.4
1240.1
962.6
1524.9
400
746.7
192
525
130.9
164.6
209.6
356.3
392.5
372.5
358.2
347.3
4.7
7
5.9
5.6
4.9
4.7
4.2
3.2
2.2
2.4

balance-sheet.row.other-liabilities

0000
0
0
0
-807.3
0
-506.3
-368.3
-397.8
-432.6
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.capital-lease-obligations

3026.2724.7471.6556.7
581.5
577.4
567.2
563.9
541.3
525.2
530.5
440.9
272.6
0
0
32.1
0
0
0
0
0
25.7
10.9
8
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-liab

19784.15149.84238.23332.5
3065
2233.2
1810.7
1503.7
1555.6
1404.4
1240.1
962.6
1524.9
1238.8
1221.5
858.5
741.6
330.2
415.6
309.8
510
531.6
437.1
449.8
386
23.2
20.1
19.6
12.7
13.7
10.7
11.5
7.1
4.9
4

balance-sheet.row.preferred-stock

0000
0
0
0
13.7
181.6
152.7
21.2
0
0
0
0
0.6
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.common-stock

520.82.62.62.5
2.6
2.6
2.5
2.5
2.5
2.4
2.4
2.3
2.1
2.1
2
2
1.5
1.3
1.2
1.1
0.8
0.8
0.8
0.8
0.6
0.3
0
0
0
0
0
0
0
0
0

balance-sheet.row.retained-earnings

34676.910142.46522.83200.8
858.7
-1853
-2989.5
-5119.7
-5373.8
-5261.8
-4705.4
-3966.9
-3521.9
-3414.8
-3444.4
-2689.8
-2047.6
-1587.8
-1196.5
-989.6
-786.2
-619.9
-423.2
-314.5
-230.5
-190.8
-149.9
-116.8
-96.9
-56.9
-35.4
-17.8
-19.9
-11.4
-6.2

balance-sheet.row.accumulated-other-comprehensive-income-loss

-70.2-14.30.815.9
-68.5
-2
0.7
-11.6
21.2
1.8
0.9
-0.3
-0.6
-1.1
-1.1
-0.6
3.2
0.9
-1
-16.3
-13
1.6
6.8
11.1
3.6
-1.1
-28.1
-23.6
-20
0
0
0
0
0
0

balance-sheet.row.other-total-stockholders-equity

28868.27449.77386.56880.8
7894
7937.6
7421.5
7157.4
6506.8
6197.5
5777.2
5321.3
4519.4
4200.7
3947.4
3784.8
2281.8
1856.9
1702.1
1244
833.8
810.4
794.2
858
659.4
434.1
424.2
416.4
247.7
142.2
140.9
67.3
63.8
63.6
11.4

balance-sheet.row.total-stockholders-equity

63995.717580.413912.710100
8686.8
6085.2
4435.2
2042.3
1338.2
1092.7
1096.2
1356.4
999.2
786.8
504
1096.9
238.9
271.3
505.9
239.2
35.4
192.8
378.6
475.4
386.9
209.2
246.2
276
130.8
85.3
105.5
49.5
43.9
52.2
5.2

balance-sheet.row.total-liabilities-and-stockholders-equity

83779.822730.218150.913432.5
11751.8
8318.5
6245.9
3546
2893.8
2497
2336.3
2319
2759.3
2204.3
1725.4
1955.5
980.5
601.5
921.6
549
545.5
724.4
815.7
925.1
772.9
232.4
266.3
295.6
143.5
99
116.2
61
51
57.1
9.2

balance-sheet.row.minority-interest

0000
0
0
0
13.7
181.6
153.7
21.2
0
235.2
178.7
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-equity

63995.717580.413912.710100
8686.8
6085.2
4435.2
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

balance-sheet.row.total-liabilities-and-total-equity

83779.8---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

Total Investments

31873.13445.6274.5729.9
670.7
699
518.1
443.7
270.9
327.7
761.8
895.8
831.8
493.6
788.2
838.3
443
105.2
491.5
302
356.2
503.9
553.3
554
66.5
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-debt

3109.9808.4561556.7
581.5
577.4
567.2
563.9
838.2
820.6
825.3
440.9
672.6
400
537
153.8
287.5
20
123.8
180.1
335
345.4
328.1
327.6
349.7
7.1
9.8
8.4
8.5
7
6.4
6
5.1
3.3
3.2

balance-sheet.row.net-debt

-37813.6-9563.9-9943-6238.3
-5406.7
-2532
-2083
-1101.5
-345.7
105.8
200
-128.4
183.2
-75.3
293.8
-292.8
-101.6
-335.7
-89.4
102.1
280
247.2
220
138.4
27.6
-24.4
-14.4
-63.1
-26.4
-21.4
-65.2
-22.6
-6.5
-24.3
-1.2

现金流量表

在 Vertex Pharmaceuticals Incorporated 的财务状况中，自由现金流在过去一段时间内发生了显著变化，呈现出 -0.165 的转变。该公司最近通过发行 134.6 扩大了股本，与上一年相比出现了0.000 的差异. 公司的投资活动产生了现金使用净额，按报告货币计算达到-3141700000.000. 与上一年相比， 8.784 发生了变化. 在同一时期，公司记录了 181.3, 6.1 和 -44.9，这对于了解公司的投资和还款策略具有重要意义. 公司的融资活动导致使用的现金净额为0.000，同比差异为0.000. 此外，公司还将0 用于向股东分红。与此同时，该公司还采取了其他财务措施，即 -224.3，这也对其在此期间的现金流产生了重大影响. 这些组成部分合在一起，全面反映了公司的财务状况和现金流管理的战略方针。

common:word.in-mln

USD
Growth
TTM202320222021202020192018201720162015201420132012201120102009200820072006200520042003200220012000199919981997199619951994199319921991

cash-flows.row.net-income

3619.63619.633222342.1
2711.6
1176.8
2087.1
91.6
-84
-588.2
-742.7
-687.5
-51.1
41.2
-754.6
-642.2
-459.9
-391.3
-206.9
-203.4
-166.2
-196.8
-108.6
-66.2
-39.7
-41
-33.1
-19.8
-40
-21.5
-17.6
2
-8.5
-5.1

cash-flows.row.depreciation-and-amortization

181.3181.3148.3125.6
109.5
106.9
72.4
61.4
61.4
62.3
63.3
48.4
38.2
35
30.5
30.1
32.2
27.5
25.9
27.3
29.6
23.4
25.4
18
9.1
6.3
4.5
3.6
3.2
3.7
3.5
3.9
2.8
1.8

cash-flows.row.deferred-income-tax

-536.5-536.5-275.9-154.6
277.3
167.4
-1512.3
-120.5
17
3.3
0.3
-285.1
36.7
-7.5
54.9
-2.2
0
-59.1
-50.2
-7.5
-4.2
-3.1
-1.5
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.stock-based-compensation

581.2581.2491.3441.4
429.5
360.5
325
290.7
237.7
231
177.5
127.3
114.3
126.8
97.7
86.7
63
59.4
39.1
7.5
4.2
3.1
1.5
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.change-in-working-capital

-265.7-265.7340.8-105.2
-54.5
-66.1
238
15.3
-2.1
-86
-11.1
-5.1
-13.8
-193.1
-63.8
61.4
138.8
47.3
123.1
-52.1
-12.7
68.9
0.9
41.1
9.8
1.5
-1.9
6.9
-3.3
1.9
-0.6
2.7
0.4
0.8

cash-flows.row.account-receivables

-84.1-84.1-358.6-274.7
-223.4
-225.6
-108.2
-71.8
-33
-104.8
7.4
53.4
39.9
-170.6
-2.9
13.9
7.8
31.6
-42.3
-8.7
-4.6
1.6
13.6
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.inventory

-322.9-322.9-136.4-92.8
-132
-64
-32
-45
-16.4
-23.1
-16.5
7.1
-29.9
-111.4
6.2
9.5
-3.2
19.5
48.2
0
0
70.8
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.account-payables

48.748.7120.831.9
51.3
-22.8
36.6
8.8
-11.7
-1.7
25
-49.2
14.9
37.5
-1.2
-15.1
19
17.4
9.2
-0.5
-5.6
-2.2
3.2
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.other-working-capital

-46.392.6715230.4
249.7
246.3
341.6
123.3
59.2
43.8
-27.1
-16.3
-38.7
51.5
-65.9
53.1
115.1
-21.2
108
-42.9
-2.5
-1.2
-16
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.other-non-cash-items

-42.6-42.6103.4-5.8
-220
-176.2
60
506.4
6.1
12
-0.5
750.4
143.6
141.3
0
38.6
-0.6
63.7
46.6
56.1
7.2
-63.2
2.8
-0.9
4.1
1.4
-0.6
-0.1
-0.2
-0.1
0
0
0
0

cash-flows.row.net-cash-provided-by-operating-activities

3537.3000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.investments-in-property-plant-an-equipment

-258.4-258.4-204.7-235
-259.8
-75.5
-95.5
-259.4
-56.6
-45.3
-51.2
-51.4
-71.1
-94.6
-38.1
-23.5
-32.2
-32.4
-32.4
-17
-12.5
-17.4
-41.2
-53.9
-11.9
-16.2
-7.9
-6
-4
-5.4
-1.9
-1.8
-1.5
-1.2

cash-flows.row.acquisitions-net

55.9-6.1-295.977
-418.2
-1154.2
0
-160
0
-80
-10
0
0
-60
0
-87.4
0
33
0
0
0
97.1
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.purchases-of-investments

-3848.5-3817.5-740.5-605.2
-450.7
-576.5
-515.4
-532.6
-629.7
-633
-1424.2
-2412.4
-1705.8
-721.5
-1234.7
-1186.7
-755.4
-318
-508.1
-236.5
-148.5
-555.8
-703
-1252.8
-1312.8
-366
-507.5
-303.6
-73
-61.9
-83.9
-48.3
-39.7
0

cash-flows.row.sales-maturities-of-investments

934.2934.2920499.3
809.9
570.9
431.6
369.2
757.6
1067.4
1557.9
2348.3
1367.9
1016
1284.8
788.3
427.6
755.6
302.4
243.4
292.4
594
728
1176.2
1088.6
428.9
495.3
191
36.2
38.3
72.3
56.8
31.6
-23.9

cash-flows.row.other-investing-activites

-24.96.10-77
418.2
0
-22.8
145.1
33.2
-40.2
1.4
61.4
-16.8
72.5
-4.7
0.6
-0.7
-33
29.6
8.3
-23.9
1.6
0.2
-14.6
-0.2
-10.3
-0.3
-0.2
0.4
0
-0.6
0
0.2
-0.1

cash-flows.row.net-cash-used-for-investing-activites

-3141.7-3141.7-321.1-340.9
99.4
-1235.3
-202.2
-437.7
104.5
268.9
74
-54.1
-425.8
212.4
7.3
-508.7
-360.6
405.2
-208.5
-1.7
107.4
119.6
-16
-145.1
-236.3
36.4
-20.4
-118.8
-40.4
-29
-14.1
6.7
-9.4
-25.2

cash-flows.row.debt-repayment

-44.9-44.9-85.5-47
-42.3
-39.2
-33.4
-319.3
-93
-20.3
-81.7
-83.7
-21.5
-250
0
-0.1
-20
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.common-stock-issued

134.6134.6186.3102
264.9
343.2
289.3
344.8
68.2
185.6
274.6
265.9
191.7
124.9
33.4
849.2
362.1
32
366
32.2
8.7
12
13.3
19.7
42.4
5.5
2.8
164.9
85.5
1.1
73.8
3.6
0.1
51.9

cash-flows.row.common-stock-repurchased

-650.5-427.6-172-1561.3
-739.4
-192
-350
0
0
0
0
0
0
0
0
290.6
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.dividends-paid

000-102
-264.9
-10
-20.8
0
0
0
0
0
0
0
0
-290.6
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.other-financing-activites

72.6-224.33.5130.3
276.4
24.8
43.8
42.9
158.1
23.7
304.5
-1.3
2
0.9
391.6
149.9
278.6
-42.2
-0.2
165.3
-17.4
25.5
0.5
-23.6
501.6
-2.7
1.4
-0.1
1.6
0.6
-1.9
-2
-1.3
-1

cash-flows.row.net-cash-used-provided-by-financing-activities

-562.2-562.2-67.7-1478
-505.3
126.8
-71.2
68.4
133.3
188.9
497.4
180.9
172.2
-124.2
425.1
999
620.7
-10.2
365.9
197.5
-8.6
37.5
13.8
-4
544
2.8
4.2
164.8
87.1
1.7
71.9
1.6
-1.2
50.9

cash-flows.row.effect-of-forex-changes-on-cash

26.926.9-29.2-13.4
20.6
1.6
-6.2
5.8
-4.7
-2.8
-2.2
4.7
-0.1
0.2
-0.4
-5.1
-0.2
0
0.2
-0.6
0.2
0.6
0.6
-0.3
-0.5
-0.1
51.5
128.2
80.7
45
28.8
-15.3
14.7
27.7

cash-flows.row.net-change-in-cash

-139.7-139.73711.9811.2
2868.2
462.4
990.7
481.5
469.2
89.5
56
79.9
14.1
232.1
-203.5
57.5
33.5
142.5
135.1
23
-43.2
-9.9
-81.1
-157.5
290.5
7.3
4.2
164.8
87.1
1.7
71.9
1.6
-1.2
50.9

cash-flows.row.cash-at-end-of-period

40937.910372.3105126800.1
5988.8
3120.7
2658.3
1665.4
1183.9
714.8
625.3
569.3
489.4
475.3
243.2
446.7
389.1
355.7
213.2
78
55
98.2
108.1
189.2
322.1
31.5
75.7
199.7
115.5
73.3
100.5
13.2
26.4
55.3

cash-flows.row.cash-at-beginning-of-period

41077.6105126800.15988.9
3120.7
2658.3
1667.5
1183.9
714.8
625.3
569.3
489.4
475.3
243.2
446.7
389.1
355.7
213.2
78
55
98.2
108.1
189.2
346.7
31.5
24.2
71.5
34.9
28.4
71.6
28.6
11.6
27.6
4.4

cash-flows.row.operating-cash-flow

3537.33537.34129.92643.5
3253.5
1569.3
1270.3
844.9
236.1
-365.4
-573.1
-60.7
267.8
143.7
-635.4
-427.6
-226.5
-252.5
-22.5
-172.1
-142.2
-167.6
-79.5
-8.1
-16.6
-31.8
-31.1
-9.4
-40.3
-16
-14.7
8.6
-5.3
-2.5

cash-flows.row.capital-expenditure

-258.4-258.4-204.7-235
-259.8
-75.5
-95.5
-259.4
-56.6
-45.3
-51.2
-51.4
-71.1
-94.6
-38.1
-23.5
-32.2
-32.4
-32.4
-17
-12.5
-17.4
-41.2
-53.9
-11.9
-16.2
-7.9
-6
-4
-5.4
-1.9
-1.8
-1.5
-1.2

cash-flows.row.free-cash-flow

3278.93278.93925.22408.5
2993.7
1493.9
1174.8
745.5
179.5
-410.7
-624.3
-170.5
196.7
49.1
-673.5
-451.1
-258.7
-284.9
-54.9
-189
-154.7
-185
-120.8
-62
-28.6
-48
-39
-15.4
-44.3
-21.4
-16.6
6.8
-6.8
-3.7

利润表行

Vertex Pharmaceuticals Incorporated 的收入与上期相比变化了 0.102%。据报告, VRTX 的毛利润为 8576.8。该公司的营业费用为 4826.6，与上年相比变化了 38.496%. 折旧和摊销费用为 181.3，与上一会计期间相比变化了 3.796%. 营业费用报告为 4826.6，显示38.496% 的同比变化。 销售和营销费用为 0, 其中 0.000% 与上年相比发生了变化。 基于近期数据的EBITDA为 0，同比增长-0.129%. 营业收入为 3750.2，与上年相比变化了-0.129%. 净利润的变化率为 0.090%。去年的净收入为3619.6.

common:word.in-mln

USD
Growth
TTM2023202220212020201920182017201620152014201320122011201020092008200720062005200420032002200120001999199819971996199519941993199219911990

income-statement-row.row.total-revenue

9869.298398930.77574.4
6205.7
4162.8
3047.6
2488.7
1702.2
1032.3
580.4
1212
1527
1410.6
143.4
102
175.5
199
216.4
160.9
102.7
69.1
161.1
167.5
78.1
61.6
44.4
43.8
13.3
22.1
19.6
27.9
3.8
3.2
2.3

income-statement-row.row.cost-of-revenue

1262.21262.21080.3904.2
736.3
547.8
409.5
275.1
210.5
125.5
61
130.3
279.9
80.5
12.7
14.2
15.7
13.9
12.2
10.1
5.6
3.1
28.3
39.6
4.1
-3.4
-4.5
-3.6
-3.2
-3.7
-3.5
-3.9
-2.8
-1.8
0

income-statement-row.row.gross-profit

86078576.87850.46670.2
5469.4
3615.1
2638.1
2213.5
1491.7
906.8
519.4
1081.7
1247.2
1330.1
130.6
87.8
159.8
185.1
204.2
150.8
97.1
66
132.8
127.9
74
65
48.9
47.4
16.5
25.8
23.1
31.8
6.6
5
2.3

income-statement-row.row.gross-profit-ratio

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

income-statement-row.row.research-development

3160.1---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.selling-general-administrative

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.selling-and-marketing-expenses

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.other-expenses

-22.8-22.8-164.84.9
296.4
192.2
-0.8
-81.4
4.1
-6.7
30.4
-72.7
45
124.8
0
0
0
0
0
0
0
0
0
0
0
6.3
4.5
3.6
3.2
3.7
3.5
3.9
2.8
1.8
0

income-statement-row.row.operating-expenses

4296.74826.634853891.2
2600
2413
1974.1
1820.7
1480.5
1373.3
1160.9
1281.1
1243
1108.4
825.2
680
618.2
597.8
429.6
292.5
234.3
238.7
252.4
196
112.7
104.6
81.3
66.6
46.3
52.3
43.8
30.6
16.6
10.6
6.4

income-statement-row.row.cost-and-expenses

5558.96088.84565.34795.4
3336.3
2960.8
2383.6
2095.8
1691
1498.8
1221.9
1411.4
1522.9
1188.9
837.9
694.2
633.9
611.7
441.7
302.6
239.9
241.8
280.7
235.6
116.8
101.2
76.8
63
43.1
48.6
40.3
26.7
13.8
8.8
6.4

income-statement-row.row.interest-income

614.7614.7144.64.9
22.2
63.7
0
0
0
0
0
0
1.9
1.9
2
5
16.3
0
23
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

income-statement-row.row.interest-expense

44.144.154.861.5
58.2
58.5
34.1
57.5
81.4
84.2
72.9
22.7
14.7
36.6
19.3
13.2
13.5
0
-8
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

income-statement-row.row.selling-and-marketing-expenses

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.total-other-income-expensenet

124.2629.6-75-51.7
260.5
197.4
-29.6
-351
2.9
-8.9
-20.5
-776.7
-1.8
-124.7
-42.7
-49.4
-1.5
-7.1
2.4
-23.5
-3.7
-82.8
-0.1
-26.1
-14.9
-0.7
0
0
-9.7
5.5
3.6
1.4
2
0.8
0

income-statement-row.row.ebitda-ratio-caps

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.other-operating-expenses

-22.8-22.8-164.84.9
296.4
192.2
-0.8
-81.4
4.1
-6.7
30.4
-72.7
45
124.8
0
0
0
0
0
0
0
0
0
0
0
6.3
4.5
3.6
3.2
3.7
3.5
3.9
2.8
1.8
0

income-statement-row.row.total-operating-expenses

124.2629.6-75-51.7
260.5
197.4
-29.6
-351
2.9
-8.9
-20.5
-776.7
-1.8
-124.7
-42.7
-49.4
-1.5
-7.1
2.4
-23.5
-3.7
-82.8
-0.1
-26.1
-14.9
-0.7
0
0
-9.7
5.5
3.6
1.4
2
0.8
0

income-statement-row.row.interest-expense

44.144.154.861.5
58.2
58.5
34.1
57.5
81.4
84.2
72.9
22.7
14.7
36.6
19.3
13.2
13.5
0
-8
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

income-statement-row.row.depreciation-and-amortization

989.2181.337.86.7
331.8
260.3
72.4
61.4
61.4
62.3
63.3
48.4
38.2
35
30.5
30.1
32.2
27.5
25.9
27.3
29.6
23.4
25.4
18
9.1
6.3
4.5
3.6
3.2
3.7
3.5
3.9
2.8
1.8
0

income-statement-row.row.ebitda-caps

4791.5---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.operating-income

3802.33750.24307.42782.1
2856.3
1197.6
635.1
123.2
9.9
-468.7
-692.4
-903.4
2.3
113.8
-696.1
-613.4
-462.7
-419.8
-229
-149.9
-154.8
-264.5
-119.6
-91.8
-38.7
-39.6
-32.4
-19.2
-29.8
-26.5
-20.7
1.2
-10
-5.6
-4.1

income-statement-row.row.income-before-tax

4379.84379.84232.42730.4
3116.8
1394.9
600.2
-15.7
-67.4
-559.6
-734.9
-976.1
-12.4
60.4
-754.6
-642.2
-464.2
-426.9
-206.9
-173.4
-158.5
-347.3
-119.7
-117.9
-53.6
-40.3
0
0
-39.5
-21
-17.1
2.1
-8
-4.8
0

income-statement-row.row.income-tax-expense

760.2760.2910.4388.3
405.2
218.1
-1486.9
-107.3
16.7
30.4
7
-288.6
38.8
19.3
19.3
19.3
-30.7
-21.4
-18.5
61.7
29
24.1
-11
-1.9
1
1.4
0.7
0.6
10.2
-5
-3.1
0.1
-1.5
-0.5
4.3

income-statement-row.row.net-income

3619.63619.633222342.1
2711.7
1176.8
2096.9
263.5
-112.1
-558.1
-738.6
-445
-107
29.6
-754.6
-641.6
-459.9
-391.3
-206.9
-203.4
-166.2
-196.8
-108.6
-66.2
-39.7
-41
-33.1
-19.8
-40
-21.5
-17.6
2
-8.5
-5.1
-4.3
类似股票
您可能还对以下内容感兴趣：
SRNE
Sorrento Therapeutics, Inc..
0.014 USD
NASDAQ
MRVI
Maravai LifeSciences Holdings, Inc..
8.8 USD
NASDAQ
CMRA
Comera Life Sciences Holdings, Inc..
0.03 USD
NASDAQ
GUBRA.CO
Gubra A/S.
296 DKK
CPH
T5O.DE
CytoTools AG.
0.468 EUR
XETRA
HBC.OL
Hofseth BioCare ASA.
2.04 NOK
OSL
6826.HK
Shanghai Haohai Biological Technology Co., Ltd..
42.05 HKD
HKSE
PPBT
Purple Biotech Ltd..
0.67 USD
NASDAQ

常见问题

什么是 Vertex Pharmaceuticals Incorporated (VRTX) 总资产是多少？

Vertex Pharmaceuticals Incorporated (VRTX) 总资产为 22730200000.000.

什么是企业年收入？

年收入为 5001200000.000.

企业利润率是多少？

公司利润率为 0.872.

什么是公司自由现金流？

自由现金流为 12.724.

什么是企业净利润率？

净利润率为 0.367.

企业总收入是多少？

总收入为 0.385.

什么是 Vertex Pharmaceuticals Incorporated (VRTX) 净利润？{{符号}}净利润（净收入）是多少？

净利润（净收入）为 3619600000.000.

公司总债务是多少？

债务总额为 808400000.000.

营业费用是多少？

运营支出为 4826600000.000.

公司现金是多少？

企业现金为 10372300000.000.